Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?-Reference-Cited by-同舟云学术

Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?

Published:2023-09 Issue:9 Volume:24 Page:e385-e394
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Cramer Allan,Sørup Freja K H,Christensen Hanne R,Petersen Tonny S,Karstoft Kristian

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Assessment of the clinical benefit of cancer drugs receiving accelerated approval;Gyawali;JAMA Intern Med,2019

2. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the us food and drug administration;Naci;JAMA,2017

3. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study;Gyawali;BMJ,2021

4. Accelerated approval - taking the FDA's concerns seriously;Sachs;N Engl J Med,2022

5. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study;Lonial;Lancet Oncol,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma;Journal of Clinical Oncology;2024-07-25

2. Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023);Expert Opinion on Therapeutic Patents;2024-07-03

3. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals;Clinical and Translational Science;2024-07

4. Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway;Journal of Pharmaceutical Policy and Practice;2024-06-04

5. Current regulatory status in China of drugs withdrawn from the US FDA accelerated pathway: implications for regulation globally;The Lancet Oncology;2024-06